Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX

Erik van Dijk, Erik van Werkhoven, Rebecca Asher, Jennifer K. Mooi, David Espinoza, Hendrik F. van Essen, Harm van Tinteren, Nicole C.T. van Grieken, Cornelis J.A. Punt, Niall C. Tebbutt, Bauke Ylstra

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX'. Together they form a unique fingerprint.

Medicine & Life Sciences